- Home
- MNOV vs EDAP Comparison
MNOV vs EDAP Comparison
Compare MNOV & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | EDAP |
|---|---|---|
| Founded | 2000 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 75.5M |
| IPO Year | 2005 | 1997 |
Fundamental Metrics
Financial Performance| Metric | MNOV | EDAP |
|---|---|---|
| Price | $1.42 | $3.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 74.7K | ★ 80.4K |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $257,917.00 | ★ $74,853,925.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.61 |
| 52 Week Low | $1.13 | $1.21 |
| 52 Week High | $2.15 | $4.00 |
Technical Indicators
Market Signals| Indicator | MNOV | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 69.02 |
| Support Level | $1.37 | $3.53 |
| Resistance Level | $1.34 | $3.45 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 71.71 | 78.52 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.